Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline

Skip NavigationMarketsPre-MarketsU.S. MarketsEurope MarketsChina MarketsAsia MarketsWorld MarketsCurrenciesPrediction MarketsCryptocurrencyFutures & CommoditiesBondsFunds & ETFsBusinessEconomyFinanceHealth & ScienceMediaReal EstateEnergyClimateTransportationInvestigationsIndustrialsRetailWealthSportsLifeSmall BusinessInvestingPersonal FinanceFintechFinancial AdvisorsOptions ActionETF StreetBuffett ArchiveEarningsTrader TalkTechCybersecurityAIEnterpriseInternetMediaMobileSocial MediaCNBC Disruptor 50Tech GuidePolitics & PolicyWhite HousePolicyDefenseCongressExpanding OpportunityEurope PoliticsChina PoliticsAsia PoliticsWorld PoliticsVideoLatest VideoFull EpisodesLivestreamTop VideoLive AudioEurope TVAsia TVCNBC PodcastsCEO InterviewsDigital OriginalsWatchlistInvesting ClubTrust PortfolioAnalysisTrade AlertsMeeting VideosHomestretchJim's ColumnsEducationSubscribePROPro NewsJosh BrownMike SantoliCalls of the DayMy PortfolioLivestreamFull EpisodesStock ScreenerMarket ForecastOptions InvestingChart InvestingSubscribeLivestreamMenuMake ItselectUSAINTLLivestreamSearch quotes, news & videosLivestreamWatchlistSIGN INCreate free accountMarketsBusinessInvestingTechPolitics & PolicyVideoWatchlistInvesting ClubPROLivestreamMenu (function() { const userMembershipOnLastVisit = localStorage.getItem("cnbcMeta__cachedUserMembership"); if (!userMembershipOnLastVisit) { // If no user membership is stored, user is likely not logged in. // These users will typically see the banner. return; } const { isPro, isInvestingClubUser } = JSON.parse(userMembershipOnLastVisit); if (!(isPro || isInvestingClubUser)) { // We’re rendering the top banner for users who are not pro or investing club members. return; } // Hide the banner for pro and investing club users. const style = document.createElement("style"); style.id = "top-banner-placeholder-style"; style.innerHTML = "[data-top-banner-placeholder] { display: none; }"; document.head.appendChild(style); })() MarketsNovo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipelinePublished Fri, Jul 31 20267:39 AM EDTUpdated Fri, Jul 31 20269:33 AM EDTElsa OhlenWATCH LIVEKey PointsNovo Nordisk shares fell after its experimental medicine, ziltivekimab, failed to show a statistically meaningful reduction in major adverse cardiovascular events in patients with certain diseases. "This does not change our strategic commitment to cardiovascular disease," chief scientific officer Martin Holst Lange said.The missed endpoint is the latest blow to the Danish drugmaker, which is racing to restore investor confidence in its pipeline and ability to execute, especially in the challenging U.S. market.In this articleNVONVOLLYFollow your favorite stocksCREATE FREE ACCOUNTShares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo.While the experimental medicine, ziltivekimab, did show some biological effect, it didn't translate into a statistically meaningful reduction in MACE, defined as cardiovascular death, non-fatal heart attack or non-fatal stroke, for patients with certain diseases, Novo said in a statement on Friday.The missed endpoint is the latest blow to the Danish drugmaker, which is racing to restore investor confidence in its pipeline and ability to execute, especially in the challenging U.S. market."While ziltivekimab did not achieve the MACE benefit we had hoped for, this does not change our strategic commitment to cardiovascular disease," chief scientific officer Martin Holst Lange said.Copenhagen-listed shares were last seen down 7.4% while its American depositary receipts were 8.6% lower in premarket trading, on track fo